The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis.
 
Elliott F. Winton
Consulting or Advisory Role - Incyte
Research Funding - Gilead Sciences (Inst); Incyte (Inst); Sanofi (Inst)
 
Timothy Devos
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Shire
 
Stephen T. Oh
Consulting or Advisory Role - Gilead Sciences; Incyte
Speakers' Bureau - Incyte
 
Uwe Platzbecker
No Relationships to Disclose
 
Martha Wadleigh
No Relationships to Disclose
 
Susie Jun
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences (I)
Travel, Accommodations, Expenses - Gilead Sciences; Gilead Sciences (I)
 
Peter Lee
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Wei Deng
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Vikas Gupta
Honoraria - Novartis
Consulting or Advisory Role - Incyte; Novartis
Research Funding - Incyte; Novartis